rayzebio

rayzebio is a company headquartered in the United States. rayzebio has been acquired. Brouky classifies it under Healthcare & Life Sciences. Brouky records 4 investors associated with the company.

RayzeBio is a biotechnology company focused on developing targeted radiopharmaceutical drugs for solid tumors in cancers. The company utilizes an iterative process involving in-vitro screening, X-ray crystallography, linker and radiolabeling optimization, and in-vivo screening with molecular imaging and biodistribution analysis to prosecute diverse sets of binders against clinically validated cancer targets.